Inozyme Pharma Inc. [INZY] stock is trading at $3.30, up 11.11%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The INZY shares have gain 16.81% over the last week, with a monthly amount glided 12.63%, and seem to be holding up well over a long-time horizon.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
On 22, March 2023, Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights. In a post published today on Yahoo Finance, – Founding CEO, Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to succeed as CEO -.
From an analyst’s perspective:
Inozyme Pharma Inc. [NASDAQ: INZY] stock has seen the most recent analyst activity on March 23, 2023, when Jefferies upgraded its rating to a Buy and also boosted its price target to $6 from $4.50. Previously, Jefferies started tracking the stock with Hold rating on May 26, 2022, and set its price target to $5. On February 07, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $33 on the stock. Needham started tracking the stock assigning a Buy rating and suggested a price target of $23 on November 29, 2021. Wedbush initiated its recommendation with a Outperform and recommended $35 as its price target on August 18, 2020. Piper Sandler started tracking with a Overweight rating for this stock on August 18, 2020, and assigned it a price target of $40. In a note dated August 18, 2020, Cowen initiated an Outperform rating.
Inozyme Pharma Inc. [INZY] stock has fluctuated between $0.99 and $6.25 over the past year. Currently, Wall Street analysts expect the stock to reach $19.33 within the next 12 months. Inozyme Pharma Inc. [NASDAQ: INZY] shares were valued at $3.30 at the most recent close of the market. An investor can expect a potential return of 485.76% based on the average INZY price forecast.
Analyzing the INZY fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -38.66, Equity is -42.36, Total Capital is -41.85, and Invested Capital is -41.94. Taking a look at the Principal structure of this organization reveals enduring liabilities to the total capital at 2.99 and enduring liabilities to the whole assets at 2.73.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.14 points at the first support level, and at 2.98 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.47, and for the 2nd resistance point, it is at 3.64.
Inozyme Pharma Inc. [INZY] reported earnings per share of -$0.38 for its fiscal quarter that ended on 9/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.43/share, meaning a difference of $0.05 and a surprise factor of 11.60%. By comparison, the stated earnings for the previous quarter ended on 6/29/2022 were -$0.38 per share as compared to estimates of -$0.48 per share, a difference of $0.1 representing a surprise of 20.80%.
Ratios To Look Out For
For context, Inozyme Pharma Inc.’s Current Ratio is 11.10. Also, the Quick Ratio is 9.92, while the Cash Ratio stands at 8.69.
Transactions by insiders
Recent insider trading involved Bjarke Henric Bjorn, SVP, COO, that happened on Dec 15 when 21500.0 shares were purchased. 10% Owner, Longitude Capital Partners III completed a deal on Apr 19 to buy 1.35 million shares. Meanwhile, Director Pivotal bioVenture Partners Fu bought 1.07 million shares on Apr 19.